Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old.

IF 5.2 4区 医学 Q2 Medicine
Joella Xiaohong Ang, Wai Yen Lee, Sun Kuie Tay
{"title":"Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old.","authors":"Joella Xiaohong Ang, Wai Yen Lee, Sun Kuie Tay","doi":"10.47102/annals-acadmedsg.2022471","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cervical screening programmes differ in the age of women recommended for primary human papillomavirus (HPV) testing. This study aims to determine the clinical efficacy and impact of 14-high-risk HPV DNA testing for women from 25 years old.</p><p><strong>Method: </strong>This was a retrospective analysis of data collected prospectively from women 25 years or older who attended hospital-based gynaecology clinics for cervical screening. Women with history of cervical neoplasia or abnormal cytology were excluded. High-risk HPV DNA testing with partial genotyping for HPV-16 and HPV-18 were performed on cobas 4800 System (Roche Diagnostics International AG, Rotkreuz, Switzerland). Women tested positive for the 12 other high-risk HPV subtypes (HPV-12 other) had a reflex cytology test. Positive screening included positive for HPV-16 and/or HPV-18, HPV-12 other with cytology abnormalities equal to or greater than atypical squamous cells of undetermined significance, and repeated positive HPV at 12 months. HPV detection and colposcopy referral rates, and detection of high-grade neoplasia were determined.</p><p><strong>Results: </strong>Of 10,967 women studied, 822 (7.50%) were HPV DNA positive. The overall discharge rate to routine screening according to screening protocol was 93.1%. Colposcopy referral rate was 4.4%. The screening detected 41 cervical intraepithelial neoplasia grade 2+ (CIN2+) (0.37%) and 31 (0.28%) CIN3+. The number of colposcopies needed per case of CIN2+ was 9.5, similar for women below and above 30 years old. The number of colposcopies needed per case of CIN3+ for HPV-16 positivity was 8.5, compared to 17.0 for other categories (P=0.040). Colposcopy efficacy was similar for HPV-18 and HPV-12 other positivity with abnormal cytology.</p><p><strong>Conclusion: </strong>Taking CIN2+ detection and colposcopy referral rate as endpoints, HPV testing in Singapore can be extended to include women from 25 years old.</p>","PeriodicalId":50774,"journal":{"name":"Annals Academy of Medicine Singapore","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2023-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals Academy of Medicine Singapore","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47102/annals-acadmedsg.2022471","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cervical screening programmes differ in the age of women recommended for primary human papillomavirus (HPV) testing. This study aims to determine the clinical efficacy and impact of 14-high-risk HPV DNA testing for women from 25 years old.

Method: This was a retrospective analysis of data collected prospectively from women 25 years or older who attended hospital-based gynaecology clinics for cervical screening. Women with history of cervical neoplasia or abnormal cytology were excluded. High-risk HPV DNA testing with partial genotyping for HPV-16 and HPV-18 were performed on cobas 4800 System (Roche Diagnostics International AG, Rotkreuz, Switzerland). Women tested positive for the 12 other high-risk HPV subtypes (HPV-12 other) had a reflex cytology test. Positive screening included positive for HPV-16 and/or HPV-18, HPV-12 other with cytology abnormalities equal to or greater than atypical squamous cells of undetermined significance, and repeated positive HPV at 12 months. HPV detection and colposcopy referral rates, and detection of high-grade neoplasia were determined.

Results: Of 10,967 women studied, 822 (7.50%) were HPV DNA positive. The overall discharge rate to routine screening according to screening protocol was 93.1%. Colposcopy referral rate was 4.4%. The screening detected 41 cervical intraepithelial neoplasia grade 2+ (CIN2+) (0.37%) and 31 (0.28%) CIN3+. The number of colposcopies needed per case of CIN2+ was 9.5, similar for women below and above 30 years old. The number of colposcopies needed per case of CIN3+ for HPV-16 positivity was 8.5, compared to 17.0 for other categories (P=0.040). Colposcopy efficacy was similar for HPV-18 and HPV-12 other positivity with abnormal cytology.

Conclusion: Taking CIN2+ detection and colposcopy referral rate as endpoints, HPV testing in Singapore can be extended to include women from 25 years old.

25岁女性原发性人乳头瘤病毒(HPV)部分基因分型筛查HPV-16和HPV-18亚型的临床疗效
引言:宫颈筛查计划因推荐进行原发性人乳头瘤病毒(HPV)检测的女性年龄而异。本研究旨在确定14项高危HPV DNA检测对25岁女性的临床疗效和影响。方法:这是对前瞻性收集的数据进行回顾性分析,这些数据来自25岁或以上的女性,她们在医院妇科诊所接受宫颈筛查。排除有宫颈肿瘤或细胞学异常病史的女性。在cobas 4800系统(Roche Diagnostics International AG,Rotkreuz,Switzerland)上进行HPV-16和HPV-18部分基因分型的高危HPV DNA检测。其他12种高危HPV亚型(HPV-12其他)检测呈阳性的女性进行了反射细胞学检测。阳性筛查包括HPV-16和/或HPV-18阳性,HPV-12其他细胞学异常等于或大于意义不明的非典型鳞状细胞,以及12个月时HPV重复阳性。确定HPV检测和阴道镜转诊率,以及高级别肿瘤的检测。结果:在10967名研究女性中,822名(7.50%)为HPV DNA阳性。根据筛查方案进行常规筛查的总出院率为93.1%。阴道镜转诊率为4.4%。筛查发现41例宫颈上皮内瘤变2级(CIN2+)(0.37%)和31例(0.28%)CIN3+。每例CIN2+所需的阴道镜检查次数为9.5次,与30岁以下和30岁以上的女性相似。HPV-16阳性每例CIN3+所需阴道镜检查次数为8.5次,而其他类别为17.0次(P=0.040)。HPV-18和HPV-12其他细胞学异常阳性的阴道镜效果相似。结论:以CIN2+检测和阴道镜转诊率为终点,新加坡的HPV检测可以扩展到25岁以上的女性。关键词:宫颈癌症筛查、宫颈上皮内瘤变、阴道镜检查、妇产科、巴氏涂片
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals Academy of Medicine Singapore
Annals Academy of Medicine Singapore 医学-医学:内科
CiteScore
4.90
自引率
5.80%
发文量
186
审稿时长
6-12 weeks
期刊介绍: The Annals is the official journal of the Academy of Medicine, Singapore. Established in 1972, Annals is the leading medical journal in Singapore which aims to publish novel findings from clinical research as well as medical practices that can benefit the medical community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信